scholarly journals A Predictive Nomogram for Early Death of Metastatic Gastric Cancer: A Retrospective Study in the SEER Database and China

2020 ◽  
Vol 11 (18) ◽  
pp. 5527-5535
Author(s):  
Ying Zhu ◽  
Xiongfeng Fang ◽  
Lanqing Wang ◽  
Tao Zhang ◽  
Dandan Yu
Keyword(s):  
Gastric Cancer ◽  
Retrospective Study ◽  
Early Death ◽  
Metastatic Gastric Cancer ◽  
Seer Database

scholarly journals Outcomes of surgery for gastric cancer with distant metastases: a retrospective study from the SEER database

Oncotarget ◽  
2016 ◽  
Vol 8 (3) ◽  
pp. 4342-4351 ◽  
Author(s):  
Jiaqi Chen ◽  
Yiyao Kong ◽  
Shanshan Weng ◽  
Caixia Dong ◽  
Lizhen Zhu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Retrospective Study ◽  
Distant Metastases ◽  
Seer Database

Association of increased survival with surgery and radiation therapy in metastatic gastric cancer: A SEER database analysis.

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 109-109
Author(s):  
Ravi Shridhar ◽  
Khaldoun Almhanna ◽  
Sarah Hoffe ◽  
William J. Fulp ◽  
Jill Weber ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Metastatic Gastric Cancer ◽  
Peritoneal Metastases ◽  
Seer Database ◽  
T Stage ◽  
Signet Ring ◽  
N Stage ◽  
Gastric Cancer Patients

109 Background: Metastatic gastric cancer has poor survival. The purpose of this study was to compare outcomes of metastatic gastric cancer patients stratified by surgery and radiation therapy. Methods: The SEER database was accessed to identify AJCC M1 stage IV (6th ed) gastric cancer patients between 2004 thru 2008. Patients were divided into 4 groups; group 1: no surgery or radiation; group 2: radiation alone; group 3: surgery alone; group 4: surgery and radiation. Survival analysis was determined by Kaplan-Meier and log-rank analysis. Multivariate analysis (MVA) was analyzed by Cox proportional hazard ratio model. Results: We identified 5072 patients. Surgery and/or radiation were associated with a survival benefit. Median and 2 year survival for groups 1, 2, 3, and 4 was 7 months and 8.2%, 8 months and 8.9%, 10 months and 18.2%, and 16 months and 31.7%, respectively (p<0.00001). MVA for all patients revealed that surgery and radiation were associated with decreased mortality while T-stage, N-stage, age, signet ring histology, and peritoneal metastases were associated with increased mortality. In patients treated with surgery, MVA showed that radiation was associated with decreased mortality while T-stage, N-stage, age, removing <15 lymph nodes, signet ring histology, and peritoneal metastases was associated increased mortality. Age was the only prognostic factor in nonsurgical patients. Conclusions: Surgery and radiation are associated with increased survival in a subset of patients with metastatic gastric cancer. Prospective trials will be needed to address the role and sequence of surgery and radiation in metastatic gastric cancer.

scholarly journals The prognostic value of age in non-metastatic gastric cancer after gastrectomy: a retrospective study in the U.S. and China

2018 ◽  
Vol 9 (7) ◽  
pp. 1188-1199 ◽  
Author(s):  
Jieyun Zhang ◽  
Lu Gan ◽  
Mi-die Xu ◽  
Mingzhu Huang ◽  
Xiaowei Zhang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Retrospective Study ◽  
Prognostic Value ◽  
Metastatic Gastric Cancer ◽  
The U.S

Hyperprogressive disease during nivolumab chemotherapy in metastatic gastric cancer: Multicenter retrospective study in Japan.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 377-377 ◽  
Author(s):  
Takeshi Suzuki ◽  
Masahiko Aoki ◽  
Hiromichi Shirasu ◽  
Naoki Takahashi ◽  
Rie Nakatsuka ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Retrospective Study ◽  
Progression Free Survival ◽  
Metastatic Gastric Cancer ◽  
Clinicopathological Characteristics ◽  
Carbohydrate Antigen ◽  
Hazard Ratio ◽  
Prior Therapy ◽  
Before And After ◽  
Hyperprogressive Disease

377 Background: Nivolumab has demonstrated a survival benefit for advanced gastric cancer (AGC). However, hyperprogressive disease (HPD) has been reported in various cancers. Methods: The subjects of this retrospective study were AGC patients with measurable disease who received nivolumab, and their tumors were assessed at least 3 times (during prior therapy, before and after nivolumab) in 24 institutions. Tumor growth rates (TGR) during nivolumab were compared to those during prior therapy as reported (Champiat S, 2017). HPD was defined as an increase in TGR > 2-fold. Results: 218 patients were identified as the subjects. While 33 (15.1%) partial response (PR) were achieved, 130 patients (59.6%) showed progression disease (PD), 38 of whom were classified as HPD (17.4%) and 2 patients showed pseudo progression (1.0%). The median progression-free survival (PFS) was 1.9 months (95% CI: 1.9–2.4) and the median overall survival (OS) was 8.5 months (95% CI: 7.1–9.6) in all patients. While patients with PD showed shorter prognosis compared with non-PD patients (median PFS: 1.5 months vs 6.4 months, hazard ratio; 6.0 [95% CI: 4.3–8.4]; p < 0.0001; median OS: 4.7 months vs not reached, hazard ratio; 4.1 [95% CI: 2.8–6.3]; p < 0.0001), there were no differences either in PFS or OS between patients with HPD and those with PD other than HPD (median PFS: 1.5 months vs 1.6 months, hazard ratio; 1.3 [95% CI: 0.9–2.0]; p = 0.1194; median OS: 5.0 months vs 4.6 months, hazard ratio; 1.0 [95% CI: 0.6–1.5]; p = 0.8695). Histological type, liver metastases, carbohydrate antigen 19-9 (CA19-9) level were associated with HPD. Conclusions: HPD was observed 17.4% in AGC patients treated with nivolumab. There were no differences either in PFS or OS between patients with HPD and those with PD other than HPD. Clinicopathological characteristics might be a predict factor for HPD.

scholarly journals MacDonald versus MAGIC treatment protocols for gastric cancer: age as a decision factor

2020 ◽  
Vol 7 (2) ◽  
pp. 190
Author(s):  
André Figueiredo ◽  
Diogo Delgado ◽  
Helena Luna Pais ◽  
Maria Filomena De Pina
Keyword(s):  
Gastric Cancer ◽  
Retrospective Study ◽  
Small Sample Size ◽  
Locally Advanced ◽  
Metastatic Gastric Cancer ◽  
Small Sample ◽  
Adjuvant Chemoradiotherapy ◽  
Cancer Center ◽  
Treatment Protocols ◽  
Risk Of Death

Background: A multimodality approach is the standard of care in the treatment of locally advanced non-metastatic gastric cancer. However, it lacks studies that compares the adjuvant chemoradiotherapy strategy of the landmark MacDonald clinical trial with the perioperative chemotherapy strategy of the landmark MAGIC clinical trial.Methods: Retrospective study of patients with gastric cancer stage IB-III treated at a single cancer center between 2010 and 2013 with MacDonald or MAGIC treatment protocols.Results: Sixty-two patients were identified (38 patients in the MacDonald protocol and 24 in the MAGIC protocol), with a mean age of 68 years (range: 39-84). At a median follow-up of 37 months, the DFS survival at 12 and 36 months of the patients in the MacDonald protocol was 83.5% and 61.1% versus 79.2% and 49.7% in the MAGIC protocol, respectively (p=0.319). The overall survival at 12 and 36 months of the patients in the MacDonald protocol was 89.5% and 65.8% versus 83.3% and 54.2% in the MAGIC protocol, respectively (p=0.168). At multivariate analysis, the risk of death was significantly superior in older patients undergoing the MAGIC protocol (p=0.02), but not the MacDonald protocol (p=0.627). The differences in toxicity between the two protocols were not statistically different.Conclusions: This result suggest that patient age is a factor to consider when choosing between the MacDonald or MAGIC protocols. However, the limitations inherent to a retrospective study of small sample size must be accounted for.

Sign in / Sign up

Export Citation Format

Share Document